on NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Prepares for Bird Flu Fight with NV-387
On February 11, 2025, NanoViricides, Inc. announced its preparedness to tackle the bird flu with NV-387, its broad-spectrum antiviral drug. NV-387 is projected to thwart the H5N1 virus, even during rapid mutations. This announcement followed an article in Scientific American critiquing the US's readiness for a human bird flu pandemic.
The company argues that previous vaccine strategies were insufficient during the COVID-19 pandemic, as the ever-evolving virus outpaced vaccine development. NanoViricides advocates for its antiviral solution, NV-387, which has shown efficacy against multiple viruses, including different flu strains and coronaviruses.
Highlighting the potential threat posed by bird flu, NanoViricides emphasizes the importance of a quick response in pandemic preparedness. With no substantial human-to-human transmission yet, the emphasis remains on preemptive measures.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NanoViricides, Inc. news